A Phase I Study of INCB7839 in Children with Recurrent High-Grade Glioma that Continues to Grow


Full Title

PBTC-056: A Phase I Study of the ADAM-10 Inhibitor, INCB007839 in Children with Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3 (CIRB)


The purpose of this study is to find the highest dose of the investigational drug INCB7839 (aderbasib) that can be given safely in children with high-grade glioma that has come back after prior treatment and continues to grow. INCB7839 targets certain growth-promoting elements in the environment surrounding the tumor, thereby starving glioma cells. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is for patients ages 3-21.
  • Patients must have a recurrent high-grade glioma of the brain or spinal cord, such as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma.
  • Patients should have recovered from the side effects of previous treatments before receiving the study drug.
  • Patients must be able to perform routine activities for more than half of their normal waking hours.

For more information about this study and to inquire about eligibility, please contact Dr. Sameer Farouk Sait at 212-639-3973.






Farouk Sait, Sameer, MD